# A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

> **NCT07078955** · PHASE2 · NOT_YET_RECRUITING · sponsor: **BRIM Biotechnology Inc.** · enrollment: 99 (estimated)

## Conditions studied

- Dry Eye Disease (DED)
- Keratoconjunctivitis Sicca

## Interventions

- **DRUG:** BRM421 Ophthalmic Solution, 0.03%
- **DRUG:** Artificial Tear
- **DRUG:** BRM421 Ophthalmic Solution, 0.06%

## Key facts

- **NCT ID:** NCT07078955
- **Lead sponsor:** BRIM Biotechnology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2026-11
- **Final completion:** 2027-03
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07078955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07078955, "A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07078955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*